All In Biotech

Drug Trial Radar · NCT00361166

Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone

A Randomized, Double Blind, Multi-Center Study to Assess the Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol or Risperidone to Schizophrenic Subjects

Last checked: Nov 20, 2026Latest source record: Mar 22, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

400

Actual

Start

Aug 2005

Primary completion

Not stated

Study completion Mar 2007

Sponsor

Lead sponsor
ACADIA Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Aug 7, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to determine whether a combination of ACP-103 (the study medication) with either haloperidol or risperidone will show antipsychotic efficacy and that it is safe and well tolerated. Further purposes of this study are to determine whether ACP-103, in combination with either haloperidol or risperidone, will enhance their antipsychotic effectiveness, demonstrate effectiveness against the negative symptoms, improve motoric tolerability, and is safe and well tolerated. This is a seven-week study (one week screening and six weeks of study medication) where a total of 400 patients who meet entrance criteria will randomly be assigned to receive one of five groups of study treatments of either low dose haloperidol plus ACP-103, low dose haloperidol plus placebo (a substance similar to a sugar pill), low dose risperidone plus ACP-103, low dose risperidone plus placebo, or high dose risperidone plus placebo. The study will begin with with a three to seven day drug-free period followed by six weeks of a stable daily dosage of study medication. Study subjects will be treated as hospital in-patients during screening and for the first 14 days of the study. Study subjects will be closely monitored throughout the study.

Conditions

  • Schizophrenia

Interventions

  • ACP-103Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total score on the Positive and Negative Symptom Scale (PANSS).

Locations

17 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Cerritos, California

  • Site not named

    Garden Grove, California

  • Site not named

    Glendale, California

  • Site not named

    Paramount, California

  • Site not named

    Pico Rivera, California

  • Site not named

    San Diego, California

  • Site not named

    San Diego, California

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    St Louis, Missouri

  • Site not named

    Austin, Texas

  • Site not named

    Irving, Texas

  • Site not named

    Salvador, Estado de Bahia, Brazil

  • Site not named

    Aparecida de Goiânia, Goiás, Brazil

  • Site not named

    Curitiba, Paraná, Brazil

  • Site not named

    Curitiba, Paraná, Brazil

  • Site not named

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Site not named

    São Paulo, São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.